Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin
Mitochondria-associated membrane collapse impairs TBK1-mediated proteostatic stress response in ALS
doi: 10.1371/journal.pone.0076941
Retinol, over longer periods, is well-established for surface fine lines and texture improvement

Food & Drug Administration, FDA Approves New Medication for Chronic Weight Management, November 2023 6 PBS, The many ways new weight loss drugs could transform the economy, June 2024 7 MarketWatch, Obesity drugs next wave: These companies could snag 20% of GLP-1 market, analysts say, August 2024 8 The Minnesota Star Tribune, Analysis finds that after 2 years GLP-1 drugs for weight loss dont justify their price, October 2024 9 PWC, From molecules to milestones: Reinventing for the future of weight loss drugs, October 2024 10 Kaiser Family Foundation KFF Health Tracking Poll, May 2024: The Publics Use and Views of GLP-1 Drugs, Accessed: 01-13-2025 11 The Washington Post, Weight-loss drugs change shopping habits, September 2024 12 Cornell, The No-Hunger Games: How GLP-1 Medicine Adoption is Changing Consumer Food Purchases, December 2024 13 Bloomberg, Ozempic is Making People Buy Less Food, Walmart Says, October 2023

Beyond the scale There is a pivotal study called the SELECT Trial, published in 2023, that showed reduction in cardiovascular events in people with overweight or obesity and cardiovascular disease who took semaglutide, Abushamat said